Related Experiment Video

Updated: Dec 28, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K

Allosteric inhibitors of the STAT3 signaling pathway

Junhong Qin1, Xiaofei Shen1, Jian Zhang2

  • 1Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Paediatrics, West China Second University Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, 610041, China.

European Journal of Medicinal Chemistry
|February 18, 2020
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for diseases like cancer. Allosteric inhibitors offer a promising approach to overcome limitations of traditional STAT3 inhibitors.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Drug Discovery

Background:

  • Signal transducer and activator of transcription 3 (STAT3) signaling is implicated in cancer, autoimmune, and inflammatory diseases.
  • STAT3 is a promising therapeutic target due to its role in various pathologies.

Purpose of the Study:

  • To review recent advances in the development of allosteric inhibitors of STAT3.
  • To discuss the applications of these novel inhibitors in treating diseases.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of preclinical and clinical data on STAT3 inhibitors.

Main Results:

  • Traditional orthosteric STAT3 inhibitors show limited clinical efficacy due to low selectivity, side effects, and resistance.
  • Allosteric inhibitors targeting STAT3 or its upstream molecules present a promising alternative.

Conclusions:

  • Allosteric inhibition is a viable strategy to overcome the limitations of orthosteric STAT3 inhibitors.
  • Further development of allosteric STAT3 inhibitors holds potential for treating various human diseases.
Keywords:
Allosteric inhibitorsAutoimmune/inflammatory diseasesCancerSTAT3

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.4K
Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential05:25

Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential

Published on: July 21, 2023

1.8K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.8K
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
62.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K